Bita Mesgarpour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4313192/publications.pdf

Version: 2024-02-01

777949 651938 33 655 13 25 citations h-index g-index papers 43 43 43 1140 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Knowledge gaps and national research priorities for COVID-19 in Iran. Health Research Policy and Systems, 2022, 20, 25.	1.1	2
2	Risk of Bias in Iranian Randomized Trials Included in Cochrane Reviews. Archives of Iranian Medicine, 2022, 25, 375-382.	0.2	0
3	How the US Sanctions Are Affecting the Health Research System in Iran?. Archives of Iranian Medicine, 2021, 24, 101-106.	0.2	9
4	Estimation of adverse drug reaction reporting in Iran: Correction for underreporting. Pharmacoepidemiology and Drug Safety, 2021, 30, 1101-1114.	0.9	7
5	Assessing research misconduct in Iran: a perspective from Iranian medical faculty members. BMC Medical Ethics, 2021, 22, 74.	1.0	8
6	Quality Assessment of Studies Included in Cochrane Oral Health Systematic Reviews: A Meta-Research. International Journal of Environmental Research and Public Health, 2021, 18, 7284.	1.2	3
7	Expectations of Health Researchers From Academic Social Network Sites: Qualitative Study. Journal of Medical Internet Research, 2021, 23, e24643.	2.1	2
8	Interventions to improve adverse drug reaction reporting: A scoping review. Pharmacoepidemiology and Drug Safety, 2020, 29, 965-992.	0.9	20
9	Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology, 2020, 34, 506-513.	2.0	19
10	Acupuncture or acupressure for pain management during labour. The Cochrane Library, 2020, 2, CD009232.	1.5	36
11	Health research system resilience: lesson learned from the COVID-19 crisis. Health Research Policy and Systems, 2020, 18, 136.	1.1	19
12	Psychometric properties of Persian version of the research misconduct questionnaire (PRMQ). Journal of Medical Ethics and History of Medicine, 2020, 13, 18.	0.6	1
13	Achievements of the Cochrane Iran Associate Centre: Lessons Learned. International Journal of Health Policy and Management, 2020, 9, 222-228.	0.5	1
14	Evaluation of Pharmacovigilance System in Iran. International Journal of Health Policy and Management, 2020, , .	0.5	2
15	A Tool to Reduce the Problems of Iranian Health Researchers. Iranian Journal of Public Health, 2020, 49, 2441-2442.	0.3	2
16	<scp>l</scp> -Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 74-81.	0.7	22
17	Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human Psychopharmacology, 2017, 32, e2583.	0.7	10
18	L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Human Psychopharmacology, 2017, 32, e2584.	0.7	25

#	Article	IF	CITATIONS
19	Harms of off-label erythropoiesis-stimulating agents for critically ill people. The Cochrane Library, 2017, 8, CD010969.	1.5	14
20	Estimating the Prevalence of Hepatitis B Virus Infection and Exposure Among General Population in Iran. Hepatitis Monthly, $2017,17,.$	0.1	12
21	Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. Iranian Journal of Psychiatry, 2017, 12, 154-162.	0.4	13
22	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care and Research, 2016, 68, 1078-1088.	1.5	24
23	SensPrecOptimizer: a software tool that combined search queries to design efficient search strategies. Journal of Clinical Epidemiology, 2016, 71, 122-123.	2.4	0
24	A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. Lipids in Health and Disease, 2015, 14, 131.	1.2	11
25	Extendedâ€release opioids in the management of cancer pain: A systematic review of efficacy and safety. European Journal of Pain, 2014, 18, 605-616.	1.4	26
26	Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Medicine, 2013, 39, 1896-1908.	3.9	24
27	Search strategies to identify reports on "off-label―drug use in EMBASE. BMC Medical Research Methodology, 2012, 12, 190.	1.4	10
28	Search strategies–identified reports on "off-label―drug use in MEDLINE. Journal of Clinical Epidemiology, 2012, 65, 827-834.	2.4	11
29	A survey of the current status of web-based databases indexing Iranian journals. Archives of Iranian Medicine, 2009, 12, 271-8.	0.2	5
30	Prevalence of social phobia and its comorbidity with psychiatric disorders in Iran. Depression and Anxiety, 2006, 23, 405-411.	2.0	21
31	An epidemiological survey of psychiatric disorders in Iran. Clinical Practice and Epidemiology in Mental Health, 2005, $1,16.$	0.6	182
32	Prevalence of obsessive-compulsive disorder in Iran. BMC Psychiatry, 2004, 4, 2.	1.1	81
33	Selegiline in Comparison with Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 418-425.	0.7	31